France
· Delayed Price · Currency is EUR Transgene Statistics
Total Valuation
Transgene has a market cap or net worth of EUR 87.11 million. The enterprise value is 80.66 million.
| Market Cap | 87.11M |
| Enterprise Value | 80.66M |
Important Dates
The last earnings date was Thursday, March 27, 2025.
| Earnings Date | Mar 27, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Transgene has 131.99 million shares outstanding. The number of shares has increased by 16.45% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 131.99M |
| Shares Change (YoY) | +16.45% |
| Shares Change (QoQ) | -0.42% |
| Owned by Insiders (%) | 70.04% |
| Owned by Institutions (%) | 1.00% |
| Float | 34.71M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 12.17 |
| PB Ratio | 5.79 |
| P/TBV Ratio | 5.75 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.37 |
| EV / Sales | 12.70 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -3.03 |
Financial Position
The company has a current ratio of 1.48, with a Debt / Equity ratio of 0.67.
| Current Ratio | 1.48 |
| Quick Ratio | 1.28 |
| Debt / Equity | 0.67 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.38 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -220.48% and return on invested capital (ROIC) is -76.42%.
| Return on Equity (ROE) | -220.48% |
| Return on Assets (ROA) | -51.00% |
| Return on Invested Capital (ROIC) | -76.42% |
| Return on Capital Employed (ROCE) | -126.49% |
| Revenue Per Employee | 43,514 |
| Profits Per Employee | -232,678 |
| Employee Count | 141 |
| Asset Turnover | 0.15 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -41.75% in the last 52 weeks. The beta is 0.79, so Transgene's price volatility has been lower than the market average.
| Beta (5Y) | 0.79 |
| 52-Week Price Change | -41.75% |
| 50-Day Moving Average | 0.69 |
| 200-Day Moving Average | 0.88 |
| Relative Strength Index (RSI) | 40.00 |
| Average Volume (20 Days) | 30,384 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Transgene had revenue of EUR 6.35 million and -33.97 million in losses. Loss per share was -0.29.
| Revenue | 6.35M |
| Gross Profit | 6.35M |
| Operating Income | -35.66M |
| Pretax Income | -33.97M |
| Net Income | -33.97M |
| EBITDA | -34.38M |
| EBIT | -35.66M |
| Loss Per Share | -0.29 |
Balance Sheet
The company has 16.67 million in cash and 10.22 million in debt, giving a net cash position of 6.46 million or 0.05 per share.
| Cash & Cash Equivalents | 16.67M |
| Total Debt | 10.22M |
| Net Cash | 6.46M |
| Net Cash Per Share | 0.05 |
| Equity (Book Value) | 15.20M |
| Book Value Per Share | 0.11 |
| Working Capital | 6.68M |
Cash Flow
In the last 12 months, operating cash flow was -23.55 million and capital expenditures -3.07 million, giving a free cash flow of -26.61 million.
| Operating Cash Flow | -23.55M |
| Capital Expenditures | -3.07M |
| Free Cash Flow | -26.61M |
| FCF Per Share | -0.20 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -561.28% |
| Pretax Margin | -534.72% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Transgene does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.45% |
| Shareholder Yield | -16.45% |
| Earnings Yield | -39.00% |
| FCF Yield | -30.55% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |